Gilead Sciences, Inc. (GILD) is a Healthcare stock trading at $143.42 (as of 2026-08-20), with a market capitalization of $178.07B and a trailing P/E of 19.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Gilead Sciences develops and commercializes prescription medicines, including HIV/AIDS treatments (such as Biktarvy and Genvoya), liver disease drugs (such as Epclusa and Vemlidy), oncology medicines (such as Yescarta and Trodelvy), and Veklury for COVID-19, and it earns money primarily from selling these medicines and from related royalty and other revenues.
Profit power is driven by recurring commercial demand for its branded, multi-indication medicine franchises, with results concentrated in a few major revenue streams (HIV and Veklury) and supported by smaller oncology and royalty or other revenue.
| HIV | $4.2B |
| Veklury | $1.5B |
| Onco | $0.6B |
| Other | $0.4B |
Business quality (Strong): Strong visibility into product-level revenue drivers, but the available breakdown is approximate, since only product revenue candidates (not explicitly confirmed reportable segments) were provided.
Valuation: At 17× earnings, GILD trades in line with the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.
| Price | $143.42 |
| Market Cap | $178.07B |
| P/E Ratio | 19.3 |
| EV / EBITDA | 17.9 |
| Price / Book | 7.60 |
| Price / Sales | 5.99 |
| FCF Yield | 5.7% |
| DCF Value (model) | $90.24 |
| DCF Upside vs Price | -37.1% |
| Revenue (TTM) | $29.44B |
| Net Margin | 28.9% |
| Revenue Growth (YoY) | 4.4% |
| EPS Growth (YoY) | 53.8% |
| FCF Growth (YoY) | 46.8% |
| Altman Z-Score | 4.45 (safe) |
| Piotroski F-Score | 8/9 (strong) |
| Stock P/E | 19.3 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | -10.5% |
| vs Industry | 12.5% |
| Top Institutional Holder | BlackRock, Inc. ($16.59B) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Daniel O'Day |
| Employees | 17,600 |
| Country | US |
| IPO Date | 1992-01-22 |
Data as of 2026-08-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.